Oxford Biomedica PLC 2016 AR2
The report highlights Oxford BioMedica's significant progress in 2016, including a 64% increase in gross income to £30.8 million, driven by the completion of its £26 million facilities expansion. The company expanded its clean room footprint three-fold and obtained regulatory approvals for GMP bioprocessing. Key partnerships were established or extended with Orchard Therapeutics, Immune Design, and Green Cross LabCell, alongside continued support for Novartis's CTL019 therapy. Environmentally, the company reported a reduction in total carbon emissions to 2,749 tonnes and successfully implemented a new Enterprise Resource Planning system to enhance operational control.
Company: Oxford Biomedica PLC
Sector: Professional & technical services
Country: United Kingdom
Year: 2016
Type: AR2
Pages: 116
Back to company
Oxford Biomedica PLC
Annual Report And Accounts
The report highlights Oxford BioMedica's significant progress in 2016, including a 64% increase in gross income to £30.8 million, driven by the completion of its £26 million facilities expansion. The company expanded its clean room footprint three-fold and obtained regulatory approvals for GMP bioprocessing. Key partnerships were established or extended with Orchard Therapeutics, Immune Design, and Green Cross LabCell, alongside continued support for Novartis's CTL019 therapy. Environmentally, the company reported a reduction in total carbon emissions to 2,749 tonnes and successfully implemented a new Enterprise Resource Planning system to enhance operational control.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Water Consumption
Women on Board
Women in Management
Employees